Abstract Number: 1546 • 2013 ACR/ARHP Annual Meeting
Patient-Reported Outcomes of Etanercept in Early Non-Radiographic Axial Spondyloarthritis: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Background/Purpose: Limited data are available on the efficacy of anti-TNF agents in non-radiographic axial spondyloarthritis (nr-axSpA). This analysis compares the impact of etanercept (ETN) vs…Abstract Number: 1547 • 2013 ACR/ARHP Annual Meeting
How The Delay In Diagnosis Impacts On The Clinical, Functional and Radiographic Status Of Patients With Ankylosing Spondylitis. Is There a Window Of Opportunity?
Background/Purpose: The delay in diagnosis has deleterious effects in patients with Rheumatoid Arthritis. This fact has not been fully investigated in patients with Ankylosing Spondylitis…Abstract Number: 1548 • 2013 ACR/ARHP Annual Meeting
Effect Of TNF Inhibitors On Bone Mineral Density In Patients With Ankylosing Spondylitis- a Systematic Review and Meta-Analysis
Background/Purpose: Patients with ankylosing spondylitis (AS) are susceptible to osteoporosis (OP) and have high fracture risk. Currently, no specific strategies are established to treat OP…Abstract Number: 1549 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Syndesmophytes In Patients With Chronic Back Pain Suspected Of Axial Spondyloarthritis (axSpA) Not Fulfilling The Modified New York (mNY) Criteria
Background/Purpose: The mNY criteria1, which indicate sacroiliitis of at least grade 2 bilaterally or grade 3 or 4 unilaterally, are used to classify patients as…Abstract Number: 1550 • 2013 ACR/ARHP Annual Meeting
Validation Of The Ankylosing Spondylitis Disease Activity Score and Effectiveness Of Infliximab In The Treatment Of Ankylosing Spondylitis Over 4 Years: The Canadian Experience
Background/Purpose: The efficacy of anti-TNF in the management of Ankylosing Spondylitis (AS) has been demonstrated in numerous controlled clinical trials. The objective of this study…Abstract Number: 1551 • 2013 ACR/ARHP Annual Meeting
The Minimum Clinically Important Improvement and Patient Acceptable Symptom State In Basdai and BASFI For Patients With Ankylosing Spondylitis
Background/Purpose: The minimum clinically important improvement (MCII) and patient acceptable symptom state (PASS) are clinically relevant measures that report the patient response and condition. We…Abstract Number: 1552 • 2013 ACR/ARHP Annual Meeting
Effective Prevention Of New Osteitis On Magnetic Resonance Imaging In Patients With Early Axial Spondyloarthritis During 3 Years Of Continous Treatment With Etanercept – Data Of The Esther Trial
Background/Purpose: In patients with early axial spondyloarthritis (SpA) with a disease duration ofAbstract Number: 1553 • 2013 ACR/ARHP Annual Meeting
Responsiveness Of Health Related Quality Of Life Questionnaires To Treatment With Anti-TNF Therapy In Psoriatic Arthritis
Background/Purpose: Patient-reported outcomes (PRO) on Health Related Quality of Life (HRQoL) are increasingly used to assess responsiveness after treatment. This study aimed to determine the…Abstract Number: 1554 • 2013 ACR/ARHP Annual Meeting
Real-World Effectiveness Of Infliximab In The Treatment Of Psoriatic Arthritis Over 12 Months: The Canadian Experience
Background/Purpose: The efficacy of anti-TNF in the management of psoriatic arthritis (PsA) has been demonstrated in numerous controlled clinical trials. Longitudinal observational studies assessing the…Abstract Number: 1555 • 2013 ACR/ARHP Annual Meeting
Anti-TNF Drug Survival In Psoriatic Arthritis Patients Treated In Ordinary Clinical Practice
Background/Purpose: The use of TNF-inhibitors in psoriatic arthritis (PsA) has been shown to improve clinical and radiographic outcome in randomized controlled trials (RCT) and shown…Abstract Number: 1556 • 2013 ACR/ARHP Annual Meeting
Paradoxical Psoriasis: Experience Of a Biological Therapy Monographic Unit
Background/Purpose: Anti TNF therapy’s efficacy in controlling cutaneous psoriasis has widely been proven, but development of paradoxical psoriasis (PPs) as a side effect can occur.…Abstract Number: 1557 • 2013 ACR/ARHP Annual Meeting
Assessing The Real Life Impact Of Psoriatic Arthritis On Disability, Quality Of Life, and Provider Satisfaction
Background/Purpose: Despite the availability of more targeted therapies for psoriatic arthritis (PsA), an assessment of the impact these have had on patient well-being has not recently…Abstract Number: 1558 • 2013 ACR/ARHP Annual Meeting
Drug Trends In Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is now recognized as a potentially severe form of arthritis which requires aggressive medical therapy. The aim of this study was…Abstract Number: 1559 • 2013 ACR/ARHP Annual Meeting
Cyclophosphamide and Rituximab Combination Treatment For Severe Systemic Lupus erythematosus is Effective and Well Tolerated
Background/Purpose: Systemic lupus erythematosus (SLE) is often complicated by resistance or partial response to initial immunosuppressive regimen and flares after initial response. Optimal management of…Abstract Number: 1560 • 2013 ACR/ARHP Annual Meeting
Clinical Characterization Of Anti-CCP+Ve Systemic Lupus Erythematosus Patients
Background/Purpose: SLE is a heterogeneous autoimmune disease characterized by the presence of autoantibodies and manifestations of numerous organ systems. One of the most common SLE…